Hikma to divest rights to five drugs in exchange for acquiring new drugs


Hikma Pharmaceuticals must sell the rights to five generic injectable drugs to Amphastar Pharmaceuticals in order to acquire drug rights from Ben Venue Laboratories. Hikma agreed to the divestitures under a proposed settlement with the Federal Trade Commission. Hikma must sell the rights to the following drugs: Acyclovir sodium injection,